LYST

Across TCGA pan-cancer cohorts, LYST mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of LYST’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where LYST mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LYST is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where LYST tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYST mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−0.616	<.001	9	view →
LUAD	Male	III,IV	−0.448	<.001	8	view →
CCRCC	All	All	+0.195	<.001	8	view →
COAD	All	All	−0.222	.006	6	view →
HNSC	Female	All	+0.430	.001	3	view →
PDAC	Male	All	−0.265	.006	3	view →
OV	All	All	−0.450	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

LYST–LSCC

Open the LSCC breakdown →